Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Braeburn/Titan Nab Powerful Ally To Push Opioid Dependence Implant

Executive Summary

With the FDA's approval in hand, the big question now is whether payers will pay for Braeburn Pharmaceuticals' and Titan Pharmaceuticals' opioid dependence implant Probuphine, whose wholesale acquisition cost has been set at $825 per month. But the companies have a strong ally on their side: Nora Volkow, head of the US National Institute of Drug Abuse, who called the product a "game-changer."


Related Content

'Norplant' Ghosts Haunt Titan/Braeburn Buprenorphine Implant
Titan plans 2nd half Probuphine resubmission on new data
FDA-backed study provides path forward for Probuphine
FDA path forward for Probuphine requires study; Titan tumbles
FDA rejects Probuphine; Mayday, Mayday, Mayday for Titan shares
Titan scores FDA panel victory for opioid addiction implant


Related Companies